Arrow Therapeutics Report issue

For profit Phase 1 Phase 2
Founded: London United Kingdom (1998)
Status: Acquired by AstraZeneca (2007)

Organization Overview

First Clinical Trial
2005
NCT00232635
First Marketed Drug
2021
lenalidomide (revlimid)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ARROW INTL

Active Ingredients

Marketed Drugs (1)

lenalidomide (revlimid) (2021)

Drugs in Phase 2 Trials (2)

azd7295 (4 trials)

rsv604 (1 trial)

Drugs in Phase 1 Trials (1)

azd4316 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Hepatitis (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Infections (Phase 2)

Respiratory Syncytial Virus Infections (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 3